AzTrials
AzTrials

Multiple MyelomaPhase 2ICONNCT04392037

Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone

A Phase 2 study testing Iberdomide plus low-dose cyclophosphamide and dexamethasone in people with Multiple Myeloma, run by Amsterdam UMC, location VUmc at 9 sites in Netherlands.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Myeloma
What is being tested?
Iberdomide plus low-dose cyclophosphamide and dexamethasone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
9 sitesNetherlands
Study dates
17 Feb 2021to Dec 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18 years.
  • Subject must have documented diagnosis of multiple myeloma and have measurable disease as defined by any of the following:
  • Serum monoclonal paraprotein (M-protein) level ≥5 g/L (0.5 g/dL); or urine M-protein level ≥200 mg/24 hours; or serum immunoglobulin free light chain ≥100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa lambda free light chain ratio (See Appendix A)
  • Relapsed or refractory disease. Relapse is defined as progression of disease after an initial response to previous treatment, more than 60 days after cessation of treatment. Refractory disease is defined as <50% reduction in M-protein or progression of disease during treatment or within 60 days after cessation of treatment.
  • Subject had 2-4 prior anti-myeloma regimens. (Note: Induction, bone marrow transplant with or without maintenance therapy is considered one regimen; Prior pomalidomide is allowed )
  • Subject has developed lenalidomide-refractory disease (any dose) during prior treatment with lenalidomide or a lenalidomide-containing regimen Lenalidomide-refractory MM is defined as progressive disease during therapy, no response (< PR) to prior lenalidomide-containing therapy, or progression within 60 days of discontinuation from lenalidomide-containing regimens, according to the International Myeloma Working Group criteria.
Show all 18Show fewer
  • WHO performance 0, 1, or 2
  • Life expectancy at least 3 months
  • Written informed consent
  • A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) and must:
  • Have two negative pregnancy tests as verified by the Investigator prior to starting study treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence* from heterosexual contact.
  • Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with two forms of contraception: one highly effective, and one additional effective (barrier) measure of contraception without interruption 28 days prior to starting investigational product, during the study treatment (including dose interruptions), and for at least 28 days after the last dose of CC-220, 90 days after the last dose of cyclophosphamide, whichever is longer. Contraception requirements are detailed in Appendix H.
  • Male subjects must:
  • Practice true abstinence* (which must be reviewed on a monthly basis and source documented) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 90 days following the last dose of study treatment, even if he has undergone a successful vasectomy.
  • True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.]
  • Males must agree to refrain from donating sperm while on study treatment, during dose interruptions and for at least 90 days following last dose of study treatment.
  • All subjects must agree to refrain from donating blood while on study treatment, during dose interruptions and for at least 28 days following the last dose of study treatment.
  • All male and female subjects must follow all requirements defined in the Pregnancy Prevention Program (v5.1). See Appendix H for CC-220 Pregnancy Prevention Plan for Subjects in Clinical Trials.

Who cannot join

  • Subjects who previously received continuous low-dose cyclophosphamide alone or in combination with other anti-MM agents are excluded (cyclophosphamide once weekly such as in bortezomib-cyclophospahmide-dexametahsone regimen (VCD) is allowed).
  • Treatment with prior iberdomide
  • Non-secretory MM
  • Systemic AL amyloidosis or plasma cell leukemia (>2.0x109/L circulating plasma cells by standard differential) or Waldenstrom's macroglobulinemia
  • Subject has known meningeal involvement of multiple myeloma
  • Inadequate marrow reserve as defined by a platelet count <75 x 109/L or an absolute neutrophil count <1.0 x 109/L
Show all 32Show fewer
  • Corrected serum calcium >13.5 mg/dL (>3.4 mmol/L)
  • Subject has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide, dexamethasone, or cyclophosphamide. Subject has known or suspected hypersensitivity to the excipients contained in the formulation of iberdomide, dexamethasone, or cyclophosphamide.
  • Subject has received any of the following within the last 14 days of initiating IberCd:
  • Plasmapheresis
  • Major surgery (as defined by the Investigator)
  • Radiation therapy other than local therapy for MM associated bone lesions
  • Use of any systemic myeloma drug therapy
  • Subject has been treated with an investigational agent (ie, an agent not commercially available) within 28 days or 5 half-lives (whichever is longer) of initiating IberCd treatment
  • Subject has current or prior use of immunosuppressive medication within 14 days prior to the first dose of IP. The following are exceptions to this criterion:
  • Intranasal, inhaled, topical or local steroid injections (eg, intra-articular injection)
  • Systemic corticosteroids at physiologic doses that do not exceed 10 mg/day of prednisone or equivalent
  • Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
  • Subject has taken a strong inhibitor or inducer of CYP3A4/5 including grapefruit, St.
  • John's Wort or related products within two weeks prior to dosing and during the course of study
  • Creatinine clearance <30 ml/min or requirement of dialysis.
  • Uncontrolled or severe cardiovascular disease (NYHA class III or IV heart failure; myocardial infarction within the last 6 months of study entry); unstable angina; unstable cardiac arrhythmias; clinically significant pericardial disease)
  • Significant hepatic dysfunction (total bilirubin ≥ 3 times normal value or transaminases ≥ 3 times normal value), unless related to myeloma
  • Subject has any concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, respiratory disease, infection, hypertension, etc.) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
  • Subject known to test positive for human immunodeficiency virus (HIV), chronic or active hepatitis B, or active hepatitis A or C
  • Peripheral neuropathy of ≥grade 2.
  • Subjects with gastrointestinal disease that may significantly alter the absorption of CC-220
  • History of active malignancy during the past 3 years, except squamous cell and basal cell carcinomas of the skin and carcinoma in situ of the cervix or breast and incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is cured, or malignancy that in the opinion of the local investigator, with concurrence with the principal investigator, is considered cured with minimal risk of recurrence within 3 years.
  • Subject is known or suspected of not being able to comply with the study protocol (eg, because of alcoholism, drug dependency, or psychological disorder) or the subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments.
  • Subject is a female who is pregnant, nursing or breastfeeding, or who intends to become pregnant during the participation in the study
  • Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis
  • Subject has previously received an allogeneic stem cell transplantation within 1 year before the date of registration and has not used immunosuppressive drugs within one month before the date of registration.

Trial locations and contacts

9 sites in 1 country.

9 sites in 1 country

Netherlands9 sites

  • NWZ

    Alkmaar

  • Amsterdam UMC, location AMC

    Amsterdam

  • Amsterdam UMC, location VUmc

    Amsterdam

  • Rijnstate

    Arnhem

  • Amphia Ziekenhuis

    Breda

  • Albert Schweitzer Ziekenhuis

    Dordrecht

  • UMC Groningen

    Groningen

  • Antonius ziekenhuis

    Nieuwegein

  • Radboud UMC

    Nijmegen

Other trials in Netherlands

About this study

Official title: A Phase 2 Study of CC220 (Iberdomide) Combined With Low-dose Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IberCd): ICON Study

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Read the detailed description

Novel drugs such as lenalidomide (an immunomodulatory drug; IMiD) have markedly improved the prognosis of multiple myeloma patients. Over the recent years, lenalidomide is increasingly used as part of first line therapy, typically until the development of progressive disease. These lenalidomide-refractory patients can be treated with several regimens. However, these regimens frequently contain proteasome inhibitors which are associated with neuropathy (bortezomib) or cardiovascular complications (carfilzomib). These proteasome inhibitors also need to be administered subcutaneously or intravenously in the hospital, once or twice per week. Also these regimens have limited efficacy in lenalidomide-refractory patients. This indicates that there is still an unmet medical need for new treatment options for patients who develop lenalidomide-refractory disease. These new treatment regimens should be active and safe without induction of neuropathy or cardiovascular side effects Moreover, an all oral regimen is frequently preferred by patients.

Iberdomide plus low-dose cyclophosphamide and dexamethasone

Available data indicates that the Cereblon E3 ligase modifying drug (CELMoD) iberdomide (CC220) is pharmacologically distinct from lenalidomide and pomalidomide with a higher potency against Cereblon, leading to differentiated antitumor and immunostimulating effects. Since iberdomide plus dexamethasone is active and well-tolerated in heavily pretreated patients including those with lenalidomide/pomalidomide-refractory disease, this two-drug regimen forms a new platform to which other agents can be added. The combinations of bortezomib, carfilzomib, or daratumumab plus iberdomide and dexamethasone are currently being evaluated.

Investigators have shown that low-dose cyclophosphamide can be effectively combined with the IMiDs lenalidomide and pomalidomide. These combinations are effective and are well-tolerated.

To address the unmet medical need for new treatment options for lenalidomide-refractory MM patients, the investigators aim at further improving the efficacy of IMiD/CELMoD plus dexamethasone combination therapy in terms of response and progression-free survival, by adding low-dose cyclophosphamide to the iberdomide-dexamethasone backbone (IberCd). This all-oral regimen will be tested in a lenalidomide-refractory patient population with 2-4 prior lines of therapy. The goal of this trial is to investigate the efficacy and safety of the IberCd combination in multiple myeloma patients who have refractory disease or a relapse after prior treatment with lenalidomide. Besides, various correlative studies will be performed during this trial including immune monitoring.

Being tested
Iberdomide plus low-dose cyclophosphamide and dexamethasone
Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Iberdomide plus low-dose cyclophosphamide and dexamethasoneDrug

    Also called CC-220

    Iberdomide, low dose Cyclophosphamide and Dexamethason will be given until progression or unacceptable toxicity

Study groups in NCT04392037
Study groupRoleWhat they receive
Iberdomide plus low-dose cyclophosphamide and dexamethasoneExperimentalIberdomide 1.6mg on days 1-21 Low-dose Cyclophosphamide 50 mg on days 1-28 of each 28 day cycle Dexamethasone 40 mg once weekly (20 mg in patients aged > 75 years)
Receives: Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Progression free survival

    PFS; i.e. time from the first dose of iberdomide-cyclophosphamide-dexamethasone to progression or death from any cause, whichever comes first

    Measured: up to 5 years

Secondary outcomes (7)

  1. Overall response rate

    In this analysis the investigators will consider the best response obtained during treatment according to the international myeloma working group (IMWG) criteria

    Measured: up to 5 years

  2. Safety and toxicity

    defined by type, frequency and severity of adverse events as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03

    Measured: up to 5 years

  3. Overall survival

    measured from first dose of iberdomide-cyclophosphamide-dexamethasone, to time of death from any cause. Patients still alive or lost to follow up are censored at the date they were last known to be alive.

    Measured: up to 5 years

  4. Time to response

    defined as time from first dose of iberdomide-cyclophosphamide-dexamethasone to the first objective documentation of PR or better.

    Measured: up to 5 years

  5. Duration of response

    defined as time from documentation of tumor response to disease progression.

    Measured: up to 5 years

  6. Time to second objective disease progression (PFS2)

    defined as time from first dose of iberdomide-cyclophosphamide-dexamethasone to 2nd disease progression or death from any cause.

    Measured: up to 5 years

  7. Time to next treatment (TTNT)

    defined as the date from first dose of iberdomide- cyclophosphamide-dexamethasone to first day when subject receives another myeloma treatment. Subjects who do not start new myeloma therapy are censored at the last known alive date or first dose date, whichever is later.

    Measured: up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2020
  2. Study start17 Feb 2021
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Patients will be treated with iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd)
Masking
None (open label)
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04392037
Sponsor's protocol ID
HAEM-2020-1
Other IDs
NL72835.029.20, 2019-004604-35, 2019
Acronym
ICON
Status last verified
Mar 2025
First submitted
13 May 2020
Last updated
28 Mar 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Korst CLBM, Plattel W, de Kort EA, Smits F, Croockewit AJ, Levin MD, Westerman M, de Weerdt O, Nijhof IS, Wegman J, Smit N, Verkleij CPM, Mutis T, Nasserinejad K, Kerstiens R, van der Klift M, Franssen LE, de Ruijter MEM, Groen K, van der Spek E, Roeloffzen WWH, Zweegman S, van de Donk NWCJ. Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2026 Jan;13(1):e30-e40. doi: 10.1016/S2352-3026(25)00298-4.

    PubMed 41482445

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Iberdomide plus low-dose cyclophosphamide and dexamethasone in people with Multiple Myeloma, run by Amsterdam UMC, location VUmc at 9 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 28 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 9 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Progression free survival (time frame: up to 5 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04392037, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in